Copart
CPRT Nasdaq Diversified Support Services Financials FY2017βFY2026
Copart's revenue rose 0.4% to $4.7 billion in fiscal 2026. Its operating margin was 35.4%, down from 36.5% a year earlier. Free cash flow was $1.3 billion, up 3.0%. It paid out $1.6 billion in dividends and buybacks, 129% of free cash flow. The diluted share count fell 2.1%.
About these figures. Share counts and per-share figures for earlier years are restated for a stock split (4-for-1), so every year is on today's share basis.
What Copart does
No business description yet.
- Legal name
- COPART, INC.
- Fiscal year ends
- July 31, 2026
- Latest annual report
- β
- Accession Β· CIK
- 0001193125-26-405731
0000900075
Revenue and margins
Copart had $4.7B of revenue in fiscal 2026, up 0.4% on the year before.
Net income and earnings per share
From fiscal 2017 to 2026, diluted EPS grew 15.9% a year. Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was $1.3B in fiscal 2026, 27.2% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Copart returned $1.6B to shareholders in fiscal 2026, 129% of free cash flow. The diluted share count fell 2.1%.
Value Copart yourself
Change the assumptions and see what they imply per share. These are models, not forecasts or price targets β the answer depends entirely on what you put in.
Discounted cash flow
Value per share
β
Adds net cash of $1.9B and divides by 956.9M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.
Earnings multiple
Value per share
β
Reference multiples: today 18.7x Β· peers 21.5x Β· sector 26.0x.
Balance sheet
Cash, debt and the ratios that show how comfortably Copart can carry it.
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.4B | $957M | $1.5B | $2.8B | $1.9B |
| Debt incl. finance leases | $0.0M | $11.0M | $0.0M | $2.7M | $2.7M |
| Net debt / EBITDA | β0.9x | β0.6x | β0.9x | β1.5x | β1.0x |
| Debt / equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | 74.2x | 568.7x | 502.7x | 840.4x | 885.6x |
| Current ratio | 5.0x | 6.6x | 7.0x | 8.4x | 7.9x |
| Quick ratio | 4.9x | 6.5x | 7.0x | 8.4x | 7.8x |
| Total assets | $5.3B | $6.7B | $8.4B | $10.1B | $10.0B |
| Total liabilities | $683M | $750M | $879M | $883M | $914M |
| Shareholders' equity | $4.6B | $6.0B | $7.5B | $9.2B | $9.1B |
| Net debt (β = net cash) | β$1.4B | β$946M | β$1.5B | β$2.8B | β$1.9B |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$9.4M
4 insiders
Of sales under plans
29%
$2.7M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 15, 2026 | Diane M MorefieldDirector | Sold | 20,000 | $27.66 | $0.6M | Form 4 |
| Jul 28, 2026 | Jeffrey LiawChief Executive Officer | Sold plan | 27,745 | $30.49 | $0.8M | Form 4 |
| Jul 13, 2026 | Daniel J EnglanderDirector | Sold | 80,000 | $27.55 | $2.2M | Form 4 |
| Apr 15, 2026 | Jeffrey LiawChief Executive Officer | Sold plan | 26,213 | $33.18 | $0.9M | Form 4 |
| Jan 15, 2026 | Jeffrey LiawChief Executive Officer | Sold plan | 25,137 | $40.17 | $1.0M | Form 4 |
| Nov 25, 2025 | Thomas N TryforosDirector | Sold | 100,000 | $39.07 | $3.9M | Form 4 |
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY24 | FY25 | FY26 |
|---|---|---|---|
| Net income is positive | β | β | β |
| Cash from operations is positive | β | β | β |
| Return on assets rose | β | β | β |
| Cash from operations exceeds net income | β | β | β |
| Debt fell relative to assets | β | β | β |
| Current ratio rose | β | β | β |
| Share count didn't rise | β | β | β |
| Gross margin rose | β | β | β |
| Revenue rose relative to assets | β | β | β |
| F-score | 5 / 8 | 4 / 8 | 4 / 8 |
| Accruals ratio | β1.4% | β2.7% | β1.2% |
| Altman Z'' | 15.72 | 17.96 | 17.34 |
Similar companies
Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score | |
|---|---|---|---|---|---|---|---|---|
| Copart CPRT | $27.8B | 0.4% | 35.4% | 27.2% | 19.6% | 18.7x | 4 | |
| RB Global RBA | $15.7B | 7.2% | 15.5% | 15.7% | 7.6% | 36.3x | 6 | Compare β |
| Science Applications Intl SAIC | $6.2B | β2.9% | 7.2% | 8.0% | 12.8% | 17.0x | 7 | Compare β |
| KBR KBR | $5.0B | 1.0% | 10.0% | 6.6% | 15.8% | 11.8x | 7 | Compare β |
| CACI International CACI | $14.1B | 10.9% | 9.6% | 8.2% | 8.8% | 26.0x | 5 | Compare β |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.4B | $1.8B | $2.0B | $2.2B | $2.7B | $3.5B | $3.9B | $4.2B | $4.6B | $4.7B |
| Gross profit | $1.3B | $1.6B | $1.8B | β | β | β | β | β | β | β |
| Operating income | $461M | $584M | $717M | $816M | $1.1B | $1.4B | $1.5B | $1.6B | $1.7B | $1.7B |
| Interest expense | $23.8M | $20.4M | $19.8M | $20.2M | $19.7M | $18.5M | $2.6M | $3.1M | $2.0M | $1.9M |
| Pretax income | $440M | $563M | $705M | $801M | $1.1B | $1.3B | $1.6B | $1.7B | $1.9B | $1.8B |
| Income tax | $45.8M | $145M | $113M | $101M | $185M | $251M | $317M | $352M | $347M | $355M |
| Net income | $394M | $418M | $592M | $700M | $937M | $1.1B | $1.2B | $1.4B | $1.6B | $1.5B |
| Diluted EPS | $0.41 | $0.43 | $0.61 | $0.73 | $0.97 | $1.13 | $1.28 | $1.40 | $1.59 | $1.55 |
| Diluted shares | 0.95B | 0.97B | 0.96B | 0.95B | 0.96B | 0.96B | 0.97B | 0.97B | 0.98B | 0.96B |
| Cash flow | ||||||||||
| Cash from operations | $492M | $535M | $647M | $918M | $991M | $1.2B | $1.4B | $1.5B | $1.8B | $1.6B |
| Capital expenditure | $172M | $288M | $374M | $592M | $463M | $337M | $517M | $511M | $569M | $337M |
| Free cash flow | $320M | $247M | $273M | $326M | $528M | $839M | $848M | $962M | $1.2B | $1.3B |
| Depreciation and amortization | $57.0M | $78.6M | $84.9M | $101M | $122M | $138M | $160M | $190M | $216M | $229M |
| Stock-based compensation | $20.8M | $23.2M | $23.4M | $23.3M | $40.9M | $39.0M | $39.7M | $35.2M | $38.0M | $38.8M |
| Acquisitions | $161M | $8.8M | $0.7M | $11.7M | $5.0M | $107M | $0.0M | $17.7M | $1.2M | $5.0M |
| Share buybacks | $0.0M | $0.0M | $365M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $1.6B |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Dividends and buybacks | $0.0M | $0.0M | $365M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $1.6B |
| Balance sheet | ||||||||||
| Cash and short-term investments | $210M | $275M | $186M | $478M | $1.0B | $1.4B | $957M | $1.5B | $2.8B | $1.9B |
| Total debt | $631M | $400M | $400M | $400M | $400M | $0.0M | $11.0M | $0.0M | $0.0M | $0.0M |
| Finance lease liabilities | $0.0M | $0.0M | $0.0M | $1.3M | $0.6M | $0.0M | $0.0M | $0.0M | $2.7M | $2.7M |
| Current assets | $587M | $709M | $687M | $964M | $1.7B | $2.2B | $3.3B | $4.4B | $5.8B | $5.6B |
| Current liabilities | $302M | $277M | $282M | $356M | $421M | $441M | $493M | $629M | $683M | $704M |
| Inventory | $10.2M | $16.7M | $20.9M | $20.1M | $45.0M | $58.8M | $40.0M | $43.6M | $39.7M | $51.4M |
| Property and equipment, net | $944M | $1.2B | $1.4B | $1.9B | $2.3B | $2.5B | $2.8B | $3.2B | $3.6B | $3.7B |
| Total assets | $2.0B | $2.3B | $2.5B | $3.5B | $4.6B | $5.3B | $6.7B | $8.4B | $10.1B | $10.0B |
| Total liabilities | $884M | $727M | $769M | $966M | $1.0B | $683M | $750M | $879M | $883M | $914M |
| Shareholders' equity | $1.1B | $1.6B | $1.8B | $2.5B | $3.5B | $4.6B | $6.0B | $7.5B | $9.2B | $9.1B |
| Margins | ||||||||||
| Gross margin | 90.5% | 89.1% | 87.5% | β | β | β | β | β | β | β |
| Operating margin | 31.9% | 32.4% | 35.1% | 37.0% | 42.2% | 39.3% | 38.4% | 37.1% | 36.5% | 35.4% |
| EBITDA margin | 35.8% | 36.7% | 39.3% | 41.6% | 46.7% | 43.2% | 42.5% | 41.6% | 41.2% | 40.3% |
| Net margin | 27.2% | 23.1% | 29.0% | 31.7% | 34.8% | 31.1% | 32.0% | 32.2% | 33.4% | 31.8% |
| FCF margin | 22.1% | 13.7% | 13.4% | 14.8% | 19.6% | 24.0% | 21.9% | 22.7% | 26.5% | 27.2% |
| Returns | ||||||||||
| Return on capital | 29.8% | 26.9% | 32.5% | 32.4% | 35.8% | 36.5% | 28.6% | 22.6% | 22.3% | 19.6% |
| Return on capital employed | 30.2% | 31.5% | 33.4% | 30.4% | 31.4% | 30.5% | 26.8% | 22.4% | 19.7% | 17.6% |
| Return on equity | 42.1% | 31.2% | 35.2% | 32.8% | 31.1% | 26.7% | 23.3% | 20.2% | 18.6% | 16.2% |
| Return on assets | 21.7% | 19.5% | 24.4% | 23.3% | 23.4% | 22.1% | 20.6% | 18.0% | 16.8% | 14.8% |
| Growth | ||||||||||
| Revenue growth | 14.2% | 24.7% | 13.1% | 8.0% | 22.1% | 30.0% | 10.5% | 9.5% | 9.7% | 0.4% |
| Net income growth | 45.8% | 6.0% | 41.6% | 18.3% | 33.8% | 16.4% | 13.5% | 10.1% | 13.9% | β4.4% |
| EPS growth | 49.6% | 4.2% | 42.2% | 19.1% | 32.4% | 16.5% | 13.3% | 9.4% | 13.6% | β2.5% |
| FCF growth | 101.7% | β22.7% | 10.4% | 19.5% | 62.0% | 59.0% | 1.0% | 13.5% | 28.0% | 3.0% |
| Share count change | β3.0% | 2.1% | β0.6% | β0.8% | 0.7% | 0.4% | 0.2% | 0.8% | 0.3% | β2.1% |
| Financial health | ||||||||||
| Net debt / EBITDA | 0.8x | 0.2x | 0.3x | β0.1x | β0.5x | β0.9x | β0.6x | β0.9x | β1.5x | β1.0x |
| Debt / equity | 0.6x | 0.3x | 0.2x | 0.2x | 0.1x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | 19.4x | 28.7x | 36.2x | 40.3x | 57.6x | 74.2x | 568.7x | 502.7x | 840.4x | 885.6x |
| Current ratio | 1.9x | 2.6x | 2.4x | 2.7x | 4.0x | 5.0x | 6.6x | 7.0x | 8.4x | 7.9x |
| Quick ratio | 1.9x | 2.5x | 2.4x | 2.7x | 3.9x | 4.9x | 6.5x | 7.0x | 8.4x | 7.8x |
| Capital allocation | ||||||||||
| Capex / revenue | 11.9% | 15.9% | 18.3% | 26.8% | 17.2% | 9.6% | 13.4% | 12.1% | 12.2% | 7.2% |
| Stock comp / revenue | 1.4% | 1.3% | 1.2% | 1.1% | 1.5% | 1.1% | 1.0% | 0.8% | 0.8% | 0.8% |
| Payouts / FCF | 0.0% | 0.0% | 133.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 128.8% |
| Quality scores | ||||||||||
| Piotroski F-score | 9.0 | 6.0 | 6.0 | 7.0 | 5.0 | 5.0 | 4.0 | 5.0 | 4.0 | 4.0 |
| Altman Z'' | 5.0 | 6.9 | 7.1 | 7.3 | 9.2 | 13.5 | 15.1 | 15.7 | 18.0 | 17.3 |
| Accruals ratio | β5.4% | β5.5% | β2.3% | β7.3% | β1.4% | β1.8% | β2.1% | β1.4% | β2.7% | β1.2% |
Source: SEC EDGAR XBRL filings (CIK 0000900075). Data updated October 9, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.